
Nanobiotix SA (NBTX) Stock Forecast & Price Target
Nanobiotix SA (NBTX) Analyst Ratings
Bulls say
Nanobiotix is a late-stage clinical biotechnology company with a positive outlook based on their innovative physics-based approach to developing nanotherapeutics for cancer treatment. The company has a strong portfolio of potential treatments, including their Nanoradioenhancer platform, Nanoprimer platform, and Neurological disease platform, with a focus on using nanoparticles to improve outcomes and minimize burden for patients. They have a partnership with JNJ and have promising preliminary data in various indications, with upcoming milestones and catalysts providing potential upside for investors.
Bears say
Nanobiotix is a clinical biotechnology company with unproven technology and a lack of current revenues or profitability. Its success hinges on the approval and uptake of its lead product candidate, JNJ-1900, and any delays or setbacks in clinical trials or regulatory approvals could negatively impact its financial stability. There are also concerns about the commercial viability of the company's novel approach and the potential for lower than expected sales post-approval. Overall, there are significant risks associated with investing in Nanobiotix, leading to a negative outlook on its stock.
This aggregate rating is based on analysts' research of Nanobiotix SA and is not a guaranteed prediction by Public.com or investment advice.
Nanobiotix SA (NBTX) Analyst Forecast & Price Prediction
Start investing in Nanobiotix SA (NBTX)
Order type
Buy in
Order amount
Est. shares
0 shares